CEO Quay: 2024 EPS at -$3.04
2024 EPS was ($3.04). "While we have consistently made meaningful and measurable progress across our (Z)-endoxifen development strategy in oncology over the last 12 months, we continue to explore the best opportunities to leverage the technology where it may help to address serious health conditions and unmet medical needs. As we continue to keep a careful eye on opportunities in the breast cancer space, we are also diligently working to advance (Z)-endoxifen in certain rare disease indications, such as Duchenne Muscular Dystrophy and McCune-Albright Syndrome," stated CEO Steven Quay. "To date, we have published work that identifies the opportunity for (Z)-endoxifen, while achieving both FDA Rare Pediatric Disease and Orphan Drug designations. We believe these FDA designations are important for future development as they both help to speed the FDA review process as well as provide potential financial benefits in the future. In the meantime, we are consciously aligning our resources with the demands of potential commercialization, even as we have added new professionals to our team to help drive both our rare disease and breast cancer programs forward. With a strong balance sheet and a strategically focused team, we believe we are well-positioned to execute and advance our clinical programs toward key value-creating milestones".
Trade with 70% Backtested Accuracy
Analyst Views on ATOS
About ATOS
About the author
Atossa Therapeutics Reports FY Losses
- Disappointing Earnings: Atossa Therapeutics reported a FY GAAP EPS of -$4.04, missing expectations by $0.22, indicating ongoing challenges in profitability that could undermine investor confidence.
- Negative Market Reaction: The failure to meet earnings expectations may put pressure on Atossa's stock price, prompting investors to monitor subsequent market dynamics and the company's strategic responses.
- Historical Financial Data: Historical financial data indicates persistent underperformance in Atossa's profitability, reflecting high costs in R&D and marketing, which may lead to increased future financing needs.
- Quantitative Rating Analysis: Seeking Alpha's quantitative rating on Atossa Therapeutics reveals a cautious market outlook regarding its future performance, necessitating close attention to the company's strategic adjustments and market reactions.
ATOS Shares Decline Post-Market Following Earnings Disappointment — CEO Focuses on Innovative Applications for Experimental Cancer Treatment
Company Financial Performance: Atossa Therapeutics reported a net loss per share of $4.04 for 2025, an increase from a loss of $3.04 in 2024, alongside rising operating expenses due to research and development costs.
FDA Designations: The company received Rare Pediatric Disease designation for its investigational therapy for Duchenne Muscular Dystrophy (DMD) in December and Orphan Drug designation in January, which are expected to expedite FDA review processes.
Stock Market Reaction: Following the financial report, Atossa's stock dropped 4% after hours, reflecting ongoing investor concerns, with the stock having fallen 50% over the past year.
Future Focus: Atossa plans to prioritize resources towards oncology and rare disease areas with higher potential returns, while it will not advance its drug for metastatic breast cancer due to cost and timeline constraints.
Atossa Therapeutics Reports 2025 Financial Results and Updates
- Financial Overview: Atossa Therapeutics reported total operating expenses of $37.1 million for 2025, an increase of 34.5% from $27.6 million in 2024, indicating rising expenditures in R&D and management that could impact future profitability.
- R&D Spending Surge: Research and development expenses reached $21.2 million in 2025, up 50% from $14.1 million in 2024, with clinical and non-clinical trial costs increasing by 60%, reflecting the company's ongoing commitment to oncology and new drug development.
- Widening Net Loss: The net loss for 2025 was $34.8 million, a 36.3% increase from $25.5 million in 2024, suggesting greater financial pressure as the company advances its product candidates, which may affect investor confidence.
- FDA Designation Progress: Atossa's (Z)-endoxifen received FDA Rare Pediatric Disease and Orphan Drug designations, which not only expedite the FDA review process but also provide potential financial benefits for future development, enhancing the company's competitive position in the market.
Atossa Therapeutics Reports 2025 Financial Results and Corporate Developments
- Financial Performance: Atossa reported total operating expenses of $37.1 million for 2025, a 34% increase from $27.6 million in 2024, primarily driven by rising R&D costs, indicating ongoing investment in clinical trials.
- R&D Progress: The FDA granted Rare Pediatric Disease designation for Atossa's (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD), highlighting its potential in treating serious conditions and the possibility of obtaining a Priority Review Voucher, enhancing market competitiveness.
- Management Team Strengthening: Atossa appointed two experienced biopharma executives as Medical Directors for Breast Oncology and Rare Diseases, aiming to bolster the company's execution capabilities in breast cancer and rare disease programs, facilitating progress toward clinical and regulatory milestones.
- Industry Recognition: Atossa received the Research and Development Excellence Award in the Precision Endocrine Therapy category at the 2025 Clinical Trials Arena Excellence Awards, underscoring its innovative efforts in advancing (Z)-endoxifen and enhancing its reputation in the biopharmaceutical sector.
ATOSSA THERAPEUTICS ANNOUNCES 2025 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS ALONG WITH A CORPORATE UPDATE
Financial Results: ATO Therapeutics reports its financial results for the fourth quarter and year-end 2025, highlighting key performance metrics and financial health.
Corporate Update: The report provides a comprehensive corporate update, detailing recent developments and strategic initiatives undertaken by the company.
Biotech Investment Revives as Institutional Capital Flows Back
- Capital Flow Trend: In early 2026, institutional investors significantly increased financing activities in the biotech sector, indicating a strong interest in clinical-stage companies with validated science, which is expected to drive industry recovery and attract more investments.
- Precision Medicine Market Outlook: The global oncology precision medicine market is projected to reach $303 billion by 2035, growing at approximately 9% annually, providing substantial market opportunities for companies focused on precision medicine, particularly in cancer treatment.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data for its drug pelareorep at the upcoming AACR Annual Meeting, with preliminary results indicating that the drug may enhance tumor sensitivity to immunotherapy, potentially altering treatment strategies.
- OS Therapies Accelerated Approval Progress: OS Therapies' OST-HER2 immunotherapy has received an elevation to a Type B meeting with the FDA, signaling a transition to accelerated approval discussions following the submission of its clinical data package, which could provide a significant competitive advantage in the market.
Atossa Therapeutics Reports FY Losses
- Disappointing Earnings: Atossa Therapeutics reported a FY GAAP EPS of -$4.04, missing expectations by $0.22, indicating ongoing challenges in profitability that could undermine investor confidence.
- Negative Market Reaction: The failure to meet earnings expectations may put pressure on Atossa's stock price, prompting investors to monitor subsequent market dynamics and the company's strategic responses.
- Historical Financial Data: Historical financial data indicates persistent underperformance in Atossa's profitability, reflecting high costs in R&D and marketing, which may lead to increased future financing needs.
- Quantitative Rating Analysis: Seeking Alpha's quantitative rating on Atossa Therapeutics reveals a cautious market outlook regarding its future performance, necessitating close attention to the company's strategic adjustments and market reactions.
ATOS Shares Decline Post-Market Following Earnings Disappointment — CEO Focuses on Innovative Applications for Experimental Cancer Treatment
Company Financial Performance: Atossa Therapeutics reported a net loss per share of $4.04 for 2025, an increase from a loss of $3.04 in 2024, alongside rising operating expenses due to research and development costs.
FDA Designations: The company received Rare Pediatric Disease designation for its investigational therapy for Duchenne Muscular Dystrophy (DMD) in December and Orphan Drug designation in January, which are expected to expedite FDA review processes.
Stock Market Reaction: Following the financial report, Atossa's stock dropped 4% after hours, reflecting ongoing investor concerns, with the stock having fallen 50% over the past year.
Future Focus: Atossa plans to prioritize resources towards oncology and rare disease areas with higher potential returns, while it will not advance its drug for metastatic breast cancer due to cost and timeline constraints.
Atossa Therapeutics Reports 2025 Financial Results and Updates
- Financial Overview: Atossa Therapeutics reported total operating expenses of $37.1 million for 2025, an increase of 34.5% from $27.6 million in 2024, indicating rising expenditures in R&D and management that could impact future profitability.
- R&D Spending Surge: Research and development expenses reached $21.2 million in 2025, up 50% from $14.1 million in 2024, with clinical and non-clinical trial costs increasing by 60%, reflecting the company's ongoing commitment to oncology and new drug development.
- Widening Net Loss: The net loss for 2025 was $34.8 million, a 36.3% increase from $25.5 million in 2024, suggesting greater financial pressure as the company advances its product candidates, which may affect investor confidence.
- FDA Designation Progress: Atossa's (Z)-endoxifen received FDA Rare Pediatric Disease and Orphan Drug designations, which not only expedite the FDA review process but also provide potential financial benefits for future development, enhancing the company's competitive position in the market.
Atossa Therapeutics Reports 2025 Financial Results and Corporate Developments
- Financial Performance: Atossa reported total operating expenses of $37.1 million for 2025, a 34% increase from $27.6 million in 2024, primarily driven by rising R&D costs, indicating ongoing investment in clinical trials.
- R&D Progress: The FDA granted Rare Pediatric Disease designation for Atossa's (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD), highlighting its potential in treating serious conditions and the possibility of obtaining a Priority Review Voucher, enhancing market competitiveness.
- Management Team Strengthening: Atossa appointed two experienced biopharma executives as Medical Directors for Breast Oncology and Rare Diseases, aiming to bolster the company's execution capabilities in breast cancer and rare disease programs, facilitating progress toward clinical and regulatory milestones.
- Industry Recognition: Atossa received the Research and Development Excellence Award in the Precision Endocrine Therapy category at the 2025 Clinical Trials Arena Excellence Awards, underscoring its innovative efforts in advancing (Z)-endoxifen and enhancing its reputation in the biopharmaceutical sector.
ATOSSA THERAPEUTICS ANNOUNCES 2025 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS ALONG WITH A CORPORATE UPDATE
Financial Results: ATO Therapeutics reports its financial results for the fourth quarter and year-end 2025, highlighting key performance metrics and financial health.
Corporate Update: The report provides a comprehensive corporate update, detailing recent developments and strategic initiatives undertaken by the company.
Biotech Investment Revives as Institutional Capital Flows Back
- Capital Flow Trend: In early 2026, institutional investors significantly increased financing activities in the biotech sector, indicating a strong interest in clinical-stage companies with validated science, which is expected to drive industry recovery and attract more investments.
- Precision Medicine Market Outlook: The global oncology precision medicine market is projected to reach $303 billion by 2035, growing at approximately 9% annually, providing substantial market opportunities for companies focused on precision medicine, particularly in cancer treatment.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data for its drug pelareorep at the upcoming AACR Annual Meeting, with preliminary results indicating that the drug may enhance tumor sensitivity to immunotherapy, potentially altering treatment strategies.
- OS Therapies Accelerated Approval Progress: OS Therapies' OST-HER2 immunotherapy has received an elevation to a Type B meeting with the FDA, signaling a transition to accelerated approval discussions following the submission of its clinical data package, which could provide a significant competitive advantage in the market.
